BioMarin Pharmaceutical Inc. (BMRN)

Rare disease medicines: operations, research, administration. Read November 8, 2026 from the annual report for the period ending December 31, 2025, filed February 26, 2026. Ranked 42 of the 145 Healthcare companies read so far, by the share within reach now.

A biopharmaceutical company whose filing counts 1,518 in operations, 495 in sales, 692 in research and development and 516 in administration, all by count.

The figures on this page come from the company's own annual report and from BLS staffing patterns for its industries, never from a roster. They are estimates with a stated method. Nothing here says what the company will do: within reach is not a forecast of jobs lost or of savings.

What follows from the reading

Share of working time within reach of AI, on the long-run pace at four in five: 36% now, 48% at the end of 2027, 52% at the end of 2028, 53% at the end of 2030. By the patterns, the work is about 53% desk work, 16% people work and 31% body work. These are the site's industry estimates weighted by the shares below: estimates with a stated method and range, not a forecast of what the company will do. By the same patterns, at the end of 2028 about 48% of the working time stays with people (conversation, in-person and hands-on work), 45% becomes checking a model's work and 5% could be handed over with lighter checks, from the industries' own figures, not the company's roles.

Headcount

3,221 employees as of December 31, 2025 (stated). North America is stated, not the U.S.: 2,026 employees in the U.S. and Canada and 1,195 outside North America (967 in Europe and the Middle East, 151 in Latin America, 77 in Asia Pacific).

The filing: “As of December 31, 2025, we had 3,221 employees worldwide, of whom 1,518 were in operations, 692 were in research and development, 495 were in sales and marketing and 516 were in administration.”

The workforce as industry patterns

What the filing says about the workforce: 3,221 employees: 1,518 operations, 692 research and development, 495 sales and marketing, 516 administration; 2,026 in the U.S. and Canada; temporary workers used for short-term positions, not counted.

Companies read with the same leading pattern

Other companies whose largest staffing pattern is also Pharmaceutical and Medicine Manufacturing, largest first, each read from its own annual report. Within reach now and at the end of 2028, long-run pace, four in five. Now is projected from METR's April 2026 measurement and Epoch's November 2026 index.

• Johnson & Johnson (JNJ, 140,800 employees)30% now, 41% by 2028
• Thermo Fisher Scientific Inc. (TMO, 125,000 employees)36% now, 53% by 2028
• Merck & Co., Inc. (MRK, 75,000 employees)32% now, 44% by 2028
• Pfizer Inc. (PFE, 75,000 employees)32% now, 44% by 2028
• AbbVie Inc. (ABBV, 57,000 employees)32% now, 44% by 2028
• Eli Lilly and Company (LLY, 50,000 employees)32% now, 44% by 2028
• Bristol-Myers Squibb Company (BMY, 32,500 employees)32% now, 44% by 2028
• Amgen Inc. (AMGN, 31,500 employees)32% now, 44% by 2028

What the filing says about AI

5 sentences in the filing name AI. Five sentences, risk factors: employees', consultants' and contractors' use of generative AI may affect intellectual property rights and is subject to privacy laws, and governments are likely to pass more laws regulating generative AI.

• “Additionally, if our employees, consultants or contractors use generative artificial intelligence (AI) technologies to develop our proprietary technology and compounds, it may impact our ability to obtain or successfully defend certain intellectual property rights.”
• “Our employees and personnel, as well as third parties with whom we work, use, or may in the future use, generative AI technologies to perform their work, and the disclosure and use of personal data in generative AI technologies is subject to various privacy laws and other privacy obligations.”
• “Governments have passed and are likely to pass additional laws regulating generative AI.”
• “If these factors limit or otherwise impair our effective use of generative AI, it could make our business less efficient and result in competitive disadvantages. 55 In addition to data privacy and security laws, we are contractually subject to industry standards adopted by industry groups and may become subject to additional such obligations in the future.”
• “Our Chief Digital and Information Officer joined us in January 2026, and has more than 20 years of experience in information technology and artificial intelligence in the biopharmaceutical industry.”

Its annual reports, year by year

Sentences naming AI in each annual report, counted by one rule, beside the median report in the Index that year. Each count links its filing. Every company, by year and sector

• Fiscal 20210median 0
• Fiscal 20220median 0
• Fiscal 20230median 1
• Fiscal 20244median 4
• Fiscal 20255median 10

Headcount by filing year

As reported in each year's annual report, with the filing. A year marked not read had no figure the reading could take from the report's text.

Limits of this reading

• The U.S. share is not stated apart from Canada (rule 7, as Cognizant's North America count).
• Temporary workers are not counted (rule 8).

Source: the company's annual report on EDGAR, accession 0001048477-26-000004, the filing. Read by Claude Fable 5.1 under rubric version 1, by the method. A company can write to info@stratussc.com to have its reading checked against its filing.